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OBJECTIVES: This is a randomized controlled trial that aims to evaluate the impact of pharmacist-led discharge
counseling on reducing pharmacotherapy problems in the 30-day postdischarge period of cardiology patients
from a tertiary hospital in Brazil.
METHODS: At discharge, two cardiovascular pharmacy residents performed a medication counseling session
with the intervention group, and the follow-up was performed by telephone (3 and 15 days after discharge).
The number of pharmacotherapy problems was evaluated during a pharmacist-led ambulatory consultation
30 days after discharge.
RESULTS: A total of 66 and 67 patients were randomized to the intervention and control groups, respectively,
but only 51 patients were analyzed in each group, all with similar baseline characteristics. The intervention
group had significantly fewer pharmacotherapy problems compared to the control (po0.001), and 100% of the
patients had at least one problem. We observed five problems significantly more frequently in the control
group: ‘‘incorrect time of taking’’ (p=0.003), ‘‘use higher dose of medication’’ (p=0.007), ‘‘use lower dose of
medication’’ (p=0.014), ‘‘restart discontinued medication’’ (p=0.011), and ‘‘underdosing prescription’’ (p=0.009).
Simvastatin, enalapril, carvedilol, and atorvastatin were the medications more associated with pharmacother-
apy problems.
CONCLUSIONS: We concluded that pharmacist-led discharge counseling should be an indispensable service,
as patients exhibited less pharmacotherapy problems in the 30-day postdischarge period, especially related to
drug administration and adherence.
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’ INTRODUCTION
Medication errors related to hospital discharge constitute
an important risk factor for rehospitalization (1). There are
several elements that contribute to increased readmission
rates, including the time to primary care follow-up, adverse
drug events (ADEs) (2-4), medication nonadherence (5,6),
medication discrepancies (7,8), insufficient discharge plan-
ning (9), and lack of continuity care (10). A retrospective
study demonstrated that 100% of the patients had at least
one ADE following hospital discharge, including minor
events, such as the need for laboratory monitoring or medi-
cation prescribed without a listed indication, and several
potentially life-threatening events, including repeated occur-
rences of hypoglycemia, altered mental status, and critical
laboratory values.
Medication discrepancies, defined as differences between
what patients think they should be taking and regimens
ordered by physicians (4), may occur when patients are
admitted or discharged from a hospital (11). Following
discharge, inaccuracies in the discharge medication list and
lack of communication between patients and health profes-
sionals may contribute to this problem (10).
Previous studies have shown that elderly polypharmacy
patients frequently have drug-related problems, which may
cause hospital admissions (12-14). Discrepancies may include
inappropriate medication omission, wrong dose, incorrect
duration, medication without a known indication, and inap-
propriate drug continuation (8).DOI: 10.6061/clinics/2019/e1091
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Coleman et al. demonstrated that patients with medica-
tion discrepancies had a 30-day hospital readmission rate of
14.3%, compared with 6.1% for patients without discrepan-
cies (p=0.04). Patients who presented any discrepancy had
used significantly more medications than those who did not
(9.0 vs. 7.1, p=0.001); most were 65 years old and older and
presented cardiology diseases, especially congestive heart
failure. The five medication classes most involved with these
problems were anticoagulants (13%), diuretics (10%), angio-
tensin-converting enzyme inhibitors (10%), lipid-lowering
agents (10%), and proton pump inhibitors (7%) (7).
Medication review, discharge medication counseling, and
telephone follow-up performed by pharmacists have been
associated with a significantly lower rate of preventable
ADEs in the 30-day postdischarge period that were related to
discrepancies, inappropriate prescribing, lack of medication
access, nonadherence, and inadequate drug monitoring (4).
Identifying medication discrepancies during hospital admis-
sion (11) and during medication reconciliation and discharge
is an important role of the clinical pharmacist. Other studies
have suggested that medication counseling prior to discharge
also improves adherence (5,15), decreases readmission rates
(1,16), and mortality (5) and consequently promotes cost
savings (16-18).
Given that discharge medication counseling can reduce
discrepancies, ADEs, and other drug-related problems and
that most of the studies were conducted in high income
countries and evaluated the endpoints by telephone, the aim
of this controlled trial was to assess the impact of a phar-
macist-led medication counseling session on pharmacother-
apy problems in the 30-day postdischarge period.
’ METHODS
This study presents a randomized controlled trial con-
ducted in a tertiary hospital of Curitiba, Brazil, from Feb-
ruary to December 2015. Patients aged 18 years and older
were eligible if they were admitted to a specialized cardio-
logy ward due to stable angina, acute coronary syndrome,
congestive heart failure, valvular disease, arrhythmias, or
hypertension. The exclusion criteria were patients with
cognitive impairment and without a caregiver, patients in
palliative care, patients transferred to other clinical special-
ties or institutions, and patients not discharged from the
hospital during the study.
Participants were assigned following randomization pro-
cedures to one of two groups in a 1:1 ratio. A random
number list was generated on Microsoft Office Excel 2010s
by a third person who was not involved in the study
to guarantee the blindness of the concealment. When the
patient was admitted to the hospital according to the
eligibility criteria, he/she was immediately allocated to this
random list according to the sequence previously generated.
The sample size was calculated considering 5.0% type I and
20% type II error (80% power) rates based on hospital
readmission rates reported in the literature, resulting in
53 patients in each group.
For the intervention group, the pharmacist reviewed the
discharge prescription and discussed significant findings
with the medical team to ensure medication use followed
evidence from guidelines. As necessary, a change in prescrip-
tion was made at this time. After that, the patients, or their
caregivers, received individual counseling sessions by the
pharmacist, which included explanations about the
indications, benefits, therapeutic targets, doses, dosing
schedule, routes, storage, length of therapy, refill pharmacy,
and possible ADEs of each prescribed drug. A leaflet
containing the information from the verbal counseling was
provided and delivered by pharmacists to optimize the
medication adherence. Afterwards, patients were contacted
by telephone by the same pharmacist at 3 and 15 days
post discharge to reinforce the previous counseling session.
All pharmacist interventions were performed according to
a novel tool entitled Descriptive Elements of Pharmacist
Interventions Characterization Tool (DEPICT) (19). The
control group received usual care by the pharmacists and
other healthcare providers. Both groups were scheduled for an
appointment 30 days post discharge at the Pharmaceutical
Care Ambulatory of the same hospital to collect data
regarding the outcomes. For more detailed methods, see the
original article (20).
The endpoints were the number of pharmacotherapy
problems and the medications related to the problems. We
defined ‘‘pharmacotherapy problems’’ as any problem related
to pharmacotherapy, including problems with a prescription,
drug administration and adherence, discrepancy between
healthcare settings, need for monitoring, ineffective treatment,
and ADEs, which could compromise the therapeutic results.
At the Pharmaceutical Care Ambulatory, after identifying the
problem, the pharmacist performed the intervention for both
groups as necessary, including suggestions of pharmacotherapy
changes (by writing a letter to the prescriber), pharmaceu-
tical counseling, laboratory test requests, and recommen-
dations for self-monitoring. The pharmaceutical consultation
returns were scheduled as required, and the therapeutic
follow-up was conducted for all patients to solve the pre-
viously discovered pharmacotherapy problems.
Statistical analyses were conducted using Statistica version
10.0. The Kolmogorov–Smirnov test was performed to assess
the normality of the distribution of the investigated para-
meters. Student’s t-tests and Mann–Whitney tests were per-
formed for continuous data as appropriate, while categorical
variables were assessed with the chi-square test. For quali-
tative analysis of the pharmacotherapy problems in both
groups, the chi-square test was also performed, considering
the presence or absence of the problems. We performed
intention-to-treat (ITT) analyses and considered p-values less
than 0.05 to be statistically significant.
This trial was in accordance with the ethical standards of
the institution’s committee (registration number: 40431015.8.
0000.0096).
’ RESULTS
Among 167 eligible patients recruited from February 2015
to November 2015, 133 patients volunteered to participate,
and 34 were excluded. A total of 66 and 67 patients were
allocated to the intervention and control groups, respectively,
and follow-up occurred until December 2015. At the end of
the study, 51 patients remained in each group (Figure 1).
There were no statistically significant differences in the
patient baseline characteristics, except for hypertension and
dyslipidemia, which were clinical conditions more prevalent
in the intervention group than in the control group (Table 1).
The mean age of the participants was 67 and 66 years in the
control and intervention groups, respectively. The majority of
the patients were male, on polypharmacy, and the most
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common comorbidities were hypertension, diabetes, coron-
ary artery disease, and dyslipidemia (Table 2).
A total of 356 pharmacotherapy problems were identified,
with 276 and 80 in the control and intervention groups,
respectively. All patients had at least one problem, although
the individuals in the control group had significantly more
than the individuals in the intervention group [4 (±4.2) vs.
1 (±1.5), po0.001]. The majority of identified problems were
related to drug administration and adherence, especially in
the control group (n=148 vs. n=19), followed by prescription
errors (n=72 vs. n=30).
The most frequent problems in the control group, which
were statistically significant compared with the intervention
group, were ‘‘incorrect time of taking’’, ‘‘use lower dose of
medication’’, ‘‘use higher dose of medication’’, ‘‘restart
discontinued medication’’, and ‘‘underdosing prescription’’
(Table 3). The drugs most commonly involved with the
identified problems were simvastatin (6.74%), enalapril
(6.74%), carvedilol (5.99%), atorvastatin (5.62%), aspirin
(5.24%), and psychiatric agents (5.24%).
Figure 1 - Flow diagram of the intervention and control groups of the randomized trial.
Table 1 - Baseline patient characteristics.
Variables* Intervention
(n = 66)
Control
(n = 67)
p**
Age 66 (±10) 67 (±12.2) 0.592
Male, n (%) 43 (55) 40 (59) 0.516
Number of comorbidities 4 (±1.6) 4 (±1.9) 0.879
Number of drugs at discharge 8 (±2.4) 8 (±2.5) 0.637
Number of drugs at ambulatory 8 (±3) 9 (±3) 0.250
Days of hospitalization*** 10 (±7.9) 11 (±8.2) 0.390
Presence of caregiver, n (%) 19 (28) 19 (28) 0.963
*Mean and standard deviation were reported for continuous data.
** Statistically significant if po0.05.
*** Two outliers were removed from the analysis because they were
hospitalized for more than 40 days while waiting for cardiac surgery.
Table 2 - Prevalence of comorbidities.
Comorbidities* Intervention
(n = 66)
Control
(n = 67)
p**
Hypertension 59 (89.4) 51 (76.1) 0.043
Diabetes mellitus 29 (43.9) 32 (47.7) 0.658
Coronary artery disease 44 (66.7) 42 (62.7) 0.631
Dyslipidemia 43 (65.1) 28 (41.8) 0.006
Congestive heart failure 23 (34.8) 31 (46.2) 0.180
Arrhythmias 14 (21.2) 9 (13.4) 0.235
Hypothyroidism 11 (16.6) 15 (22.4) 0.405
Smoking 10 (15.1) 11 (16.4) 0.841
Stroke, previous 8 (12.1) 9 (13.4) 0.821
Benign prostatic
hyperplasia
5 (7.5) 4 (5.9) 0.387
Valvulopathies 5 (7.6) 3 (4.5) 0.350
Chronic kidney disease 3 (4.5) 6 (8.9) 0.254
Gout 3 (4.5) 0 0.237
Depression 2 (3.0) 1 (1.5) 0.309
Cardiomyopathies 1 (1.5) 2 (2.9) 0.505
Fibromyalgia 1 (1.5) 2 (2.9) 0.505
Others 8 (12.1) 10 (14.9) 0.636
* The mean and % (in parentheses) were reported for each comorbidity.
**po0.05 indicates significance.
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Other frequent problems were related to monitoring
(especially self-monitoring and the need for laboratory tests)
and ‘‘clinical health condition without treatment’’, but the
differences between the groups were not significant (Table 3).
Additionally, our previous publication about the same
study showed that the intervention group had a significantly
lower readmission rate related to heart disease than the
control group (0% vs. 11.3%, p=0.027) (20). Therefore, the
incidence of pharmacotherapy problems in the control
group, especially those problems with higher clinical signif-
icance, could contribute to hospital readmission.
’ DISCUSSION
According to Cipolle et al., a medication-related problem
[or drug-related problem (DRP)] occurs when a patient
experiences or is likely to experience a disease or a
symptom having an actual or suspected relationship with
pharmacotherapy (21). Moreover, Varkey et al. defined
medication discrepancy as a difference in drug name,
dose, frequency, and mode of administration between the
medical record and the patient-generated report (22).
In this study, ‘‘pharmacotherapy problems’’ included all
problems related to medications, which included the
concept of medication-related problems and medication
discrepancy.
According to Bech et al., DRPs with higher clinical
relevance require medical consultation or hospital admission,
while DRPs with lower clinical relevance can be solved
by other health professionals and do not require medical
attention, e.g., by pharmacist-provided patient counseling
on the correct use of the medicine (23). In this study, most
pharmacotherapy problems with higher clinical relevance
were those related to prescriptions errors, which required
medical consultation to solve them. As mentioned above, the
control group had more clinically relevant pharmacotherapy
problems than the intervention group (n=72 vs. n=30).
The results of this study demonstrate the contribution of
the pharmacist in reducing pharmacotherapy problems
30 days after hospital discharge, especially problems related
to incorrect time of taking the drug, using lower and higher
doses, restarting a discontinued medication, and under-
dosing prescription. ‘‘Clinical condition without treatment’’
and ‘‘need for monitoring’’, especially self-monitoring, were
frequent problems identified in the 30-day postdischarge
period, indicating the importance of follow-up of cardiology
patients to identify pharmacotherapy problems. Moreover,
100% of patients had at least one pharmacotherapy problem
since most of them were elderly polypharmacy patients,
representing a population susceptible to DRPs (12), and cons-
equently to hospital readmission (7,8).
According to Farley et al., clinically important medication
discrepancies in the primary care physician record were
Table 3 - Number of pharmacotherapy problems.
Pharmacotherapy problem Intervention* Control* p**
Related to the prescription Clinical condition without treatment 10 14 0.389
Underdosing prescription 1 9 0.009
Needs additional drug therapy 4 7 0.274
Availability of more cost-effective alternative
therapy
4 7 0.274
Unnecessary drug therapy 3 6 0.254
Inappropriate drug 2 5 0.226
Need for preventive drug 0 4 0.131
Availability of more effective alternative therapy 2 3 0.507
Overdosing prescription 0 2 0.483
Availability of safer alternative therapy 0 2 0.483
Incorrect treatment duration 1 1 0.748
Frequency or incorrect administration time 0 1 0.994
Duplicate therapy 1 1 0.748
Other pharmacotherapy problems 0 2 0.565
Related to medication administration and medication
adherence
Incorrect time of drug taking 2 16 0.003
Use higher dose of medication 3 13 0.007
Use lower dose of medication 3 12 0.014
Discontinuation of prescribed medication 5 9 0.207
Restart discontinued medication 0 8 0.011
Inappropriate self-medication 1 4 0.187
Administration of the wrong drug 1 3 0.315
Incorrect administration technique 2 3 0.507
Patient did not start treatment 1 3 0.315
Incorrect treatment duration 0 1 0.994
Abrupt reduction in dose 0 1 0.994
Abuse of the drug 0 1 0.994
Other pharmacotherapy problems 1 3 0.315
Discrepancies between healthcare settings Omission of prescribed drug 2 4 0.331
Discrepant drug 0 1 0.994
Monitoring Need for self-monitoring 10 14 0.389
Need for laboratory test 9 13 0.371
Need for nonlaboratory test 2 2 0.685
Other Adverse drug event 6 6 0.978
Ineffective treatment 3 6 0.254
* Intention-to-treat analyses: considering the number of randomized patients.
**po0.05 indicates significance.
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different between patients who received a clinical pharma-
cist’s intervention during hospital admission and discharge.
However, this effect was sustained at 30 days post discharge
(p=0.013) but not at 90 days (11). Our study confirms the
need for involving pharmacists at hospital discharge, as
patients who received medication counseling had signifi-
cantly less pharmacotherapy problems than patients with
standard care in the 30 days after discharge, especially with
respect to drug administration and adherence.
A descriptive analysis from a larger randomized trial
demonstrated that the mean number of DRPs was similar to
that in the control group in the present study, 3.9 (±3.2), and
the most prevalent was ‘‘patient requires drug therapy’’,
which was frequently involved with respiratory, cardiovas-
cular, and musculoskeletal systems (13). Another rando-
mized controlled trial, performed only with patients with
heart failure, revealed that restarting discontinued medica-
tion and using higher doses of medication were discrepan-
cies more common in the control group (24), consistent with
our study.
An observational study with more than 400 patients with
any pathology demonstrated that the more frequent pre-
ventable ADEs were nonadherence and underuse (18%),
untreated medical problem (15%), and laboratory test needed
(13%), and each patient had an ADE mean of 2.9 (±4).
More than half of the ADEs could be attributed to three
classes of medications: antihypertensives (23%), hypogly-
cemics (15%), and psychiatric drugs (11%) (3). We also
observed that the most prevalent problems were related
to medication administration and nonadherence, and the
therapeutic classes most commonly associated with pro-
blems were lipid-lowering drugs (simvastatin and atorvas-
tatin), antihypertensives (enalapril and carvedilol), an
antiplatelet (aspirin), and psychiatric drugs. Another study
found that cardiovascular and lipid-lowering agents were
some of the drugs most related to ADEs during the first 30
days after discharge (2).
Limitations of this study include a small patient popula-
tion and a researcher-led intervention randomized trial,
which is inherent to the study design. Other limitations
include the relatively short postdischarge follow-up and
the inability to extend the results to patients with other
clinical issues. However, cardiovascular diseases are one of
the major causes of hospitalization and mortality worldwide,
and patients with these conditions could benefit from the
interventions performed in this study. Moreover, even with
a small population and a short follow-up, the discharge
medication counseling performed by pharmacists showed
a significant reduction in pharmacotherapy problems;
however, it will be necessary to conduct additional studies
with a longer follow-up to determine if the results remain
significant.
’ CONCLUSIONS
This study demonstrated the need for a pharmacist to
perform discharge medication counseling to reduce pharma-
cotherapy problems in cardiology patients with polyphar-
macy, especially the problems related to drug administration
and adherence, since these problems were significantly less
frequent in the intervention group: ‘‘incorrect time of
taking’’, ‘‘use higher dose of medication’’, ‘‘use lower dose
of medication’’, ‘‘restart discontinued medication’’, and
‘‘underdosing prescription’’. The transition of care is a
high-risk situation for many patients, and thus discharge
counseling and follow-up are necessary to prevent pharma-
cotherapy problems and clinical outcomes.
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